TransMedics Group, Inc. (TMDX) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin compression ⢠Free cash flow ⢠Rising leverage TMDX remains highly profitable with strong liquidity, but margin compression, negative Q1 free cash flow, and rising leverage temper the outlook despite still-elevated valuation multiples.
Price Behavior
Key Price Behavior Insights: ⢠Momentum break ⢠Higher lows ⢠Range bound Support Level: $67.20-$67.50 Resistance Level: $71.40-$72.90 TMDX is showing a fragile rebound after a sharp mid-May momentum break, but it still needs a clean move above $71.40-$72.90 to confirm a durable uptrend.
Sentiment & News
Key News Insights: ⢠Revenue growth ⢠Margin pressure ⢠Expansion rollout TransMedics still has a strong growth story with rising revenue and major expansion initiatives, but investors remain focused on weak profitability, higher spending, and execution risk.
AI Summary
TMDX has shifted from a pure high-growth medtech story to a proof-of-execution case, as solid revenue growth is now being offset by margin compression, rising leverage, and negative free cash flowâso the stock likely won't re-rate until management shows that expansion can translate into durable profitability and cleaner cash generation.
Description
TransMedics Group is a commercial-stage medical technology company that develops and commercializes portable systems for perfusion, preservation and monitoring of donor organs to support transplantation in the U.S. and abroad. Its Organ Care System recreates near-physiologic conditions ex vivo and includes device variants for lungs, hearts and livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 25 | Jan 1 | TMDX | TransMedics Group, Inc. | TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea. | Closed | -4.2% |
| Sep 8 | Sep 15 | TMDX | TransMedics Group, Inc. | TransMedics delivered robust Q2 revenue (+38% YoY), raised 2025 guidance, received an FDA conditional approval for a key trial (Aug 2025), and shows strong technical momentum with clear near-term catalysts, although ongoing litigation and valuation levels advise cautious position sizing. | Closed | +8.3% |